Therapeutic significance of hormone receptor positivity in patients with HER-2 positive breast cancer
Authors:
Open Access
- 11 December 2019
- journal article
- review article
- Published by Palacky University Olomouc in Biomedical Papers
- Vol. 163 (4) , 285-292
Abstract
Breast cancer with high expression of human epidermal growth factor receptor (HER)-2 represents a biologically and clinically heterogeneous group of neoplastic disorders. Importantly, hormone receptor expression has an effect on biological pro...Keywords
This publication has 57 references indexed in Scilit:
- Bidirectional Crosstalk between the Estrogen Receptor and Human Epidermal Growth Factor Receptor 2 Signaling Pathways in Breast Cancer: Molecular Basis and Clinical ImplicationsBreast Care, 2013
- Adding hormonal therapy to chemotherapy and trastuzumab improves prognosis in patients with hormone receptor-positive and human epidermal growth factor receptor 2-positive primary breast cancerBreast Cancer Research and Treatment, 2012
- Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort studyBreast Cancer Research, 2012
- Therapeutic implications of estrogen receptor signaling in HER2-positive breast cancersBreast Cancer Research and Treatment, 2012
- Different mechanisms for resistance to trastuzumab versus lapatinib in HER2- positive breast cancers - role of estrogen receptor and HER2 reactivationBreast Cancer Research, 2011
- Estrogen Receptor and Progesterone Receptor As Predictive Biomarkers of Response to Endocrine Therapy: A Prospectively Powered Pathology Study in the Tamoxifen and Exemestane Adjuvant Multinational TrialJournal of Clinical Oncology, 2011
- Mechanisms of Endocrine Resistance in Breast CancerAnnual Review of Medicine, 2011
- Lapatinib plus Letrozole as First-Line Therapy for HER-2+ Hormone Receptor–Positive Metastatic Breast CancerThe Oncologist, 2010
- Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2–Positive, Hormone Receptor–Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM StudyJournal of Clinical Oncology, 2009
- Increasing steroid hormone receptors expression defines breast cancer subtypes non responsive to preoperative chemotherapyBreast Cancer Research and Treatment, 2008